Related Experiment Videos
Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study
Thomas J A Lehman1, Sharon J Schechter, Robert P Sundel
1Division of Pediatric Rheumatology, Hospital for Special Surgery, and the Department of Pediatrics, Sanford Weill Medical College of Cornell University, New York, New York, USA.
The Journal of Pediatrics
|December 8, 2004
Summary
Thalidomide treatment helped most children with severe systemic onset juvenile rheumatoid arthritis reduce prednisone use. This therapeutic approach also improved key inflammatory markers and hemoglobin levels in patients with this chronic condition.
Area of Science:
- Pediatric Rheumatology
- Pharmacology
Background:
- Systemic onset juvenile rheumatoid arthritis (sJIA) is a severe autoimmune disease affecting children.
- Managing sJIA often involves corticosteroids like prednisone, which have significant side effects.
- Difficult cases of sJIA require alternative or adjunctive treatments.
Purpose of the Study:
- To evaluate the efficacy of thalidomide in treating children with refractory systemic onset juvenile rheumatoid arthritis.
- To assess thalidomide's impact on prednisone requirements and disease activity markers.
Main Methods:
- A cohort of 13 children diagnosed with difficult systemic onset juvenile rheumatoid arthritis was treated with thalidomide.
- Treatment outcomes were assessed at a 6-month follow-up period.
- Key outcome measures included prednisone usage, erythrocyte sedimentation rate (ESR), hemoglobin levels, and sJIA improvement scores.
Main Results:
- Eleven out of 13 children (84.6%) successfully reduced their prednisone dosage.
- A statistically significant decrease in prednisone use was observed (P < .002).
- Concurrent improvements included reduced ESR (P < .0001), increased hemoglobin (P < 0.005), and >/=50% improvement scores in 10 children (76.9%).
Conclusions:
- Thalidomide demonstrates significant therapeutic potential as an adjunctive treatment for children with difficult systemic onset juvenile rheumatoid arthritis.
- This treatment can lead to reduced corticosteroid dependence and improved disease control.
- Further research into thalidomide's long-term efficacy and safety in pediatric rheumatology is warranted.